StreetInsider.com News Articles

Solid Biosciences (SLDB) PT Raised to $26 at Cantor Fitzgerald Before INSPIRE Ph1/2 Readout

Thu, 27 Aug 2026 07:30:24 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Solid Biosciences (NASDAQ: SLDB) to $26.00 (from $16.00) while maintaining an Overweight rating.

The analyst commented, "SLDB has a key upcoming catalyst: the first functional data readout from the Phase 1/2 INSPIRE study of SGT-003 (AAV-based gene therapy) in DMD, expected YE26/Early 27. This readout will be the first opportunity to determine whether SGT-003's differentiated construct and robust biomarker profile translate into functional benefit. Against this backdrop, we benchmark SGT-003 against competing AAVbased gene therapies, RGX-202 (RGNX; NC) and ELEVIDYS (SRPT; N). We believe SGT-003 has the potential to become a

Solid Biosciences (SLDB) PT Raised to $26 at Cantor Fitzgerald Before INSPIRE Ph1/2 Readout

Thu, 27 Aug 2026 07:30:24 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Solid Biosciences (NASDAQ: SLDB) to $26.00 (from $16.00) while maintaining an Overweight rating.

Truist Securities Assumes Solid Biosciences (SLDB) at Buy

Fri, 21 Aug 2026 05:13:21 -0400

Truist Securities analyst Danielle Bril assumes coverage on Solid Biosciences (NASDAQ: SLDB) with a Buy rating and a price target of $20.00.

For an analyst ratings summary and ratings history on Solid Biosciences click here. For more ratings news on Solid Biosciences click here.

Shares of Solid Biosciences closed at $9.10 yesterday.

Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932875.html

Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932875.html

Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930565.html

Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930565.html

Solid Biosciences (SLDB) Reiterated at Market Outperform by Citizens on Continued Execution

Mon, 10 Aug 2026 04:26:12 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $15.00 price target on Solid Biosciences (NASDAQ: SLDB).

The analyst commented, "Solid Biosciences reported 2Q26 financial results and highlighted continued execution across its genetic medicine pipeline, led by Duchenne muscular dystrophy (DMD) gene therapy SGT-003. The third, and critical, FDA interaction regarding SGT-003 is on track for 4Q26. Meanwhile, SLDB anticipates dosing patients with its third novel gene therapy, SGT-501 indicated for Catecholaminergic polymorphic ventricular tachycardia (CPVT), in 2H26. With more clarity on the route ahead for SGT-003 in DMD coming soon and a more gene Tx-friendly FDA, we maintain our

Solid Biosciences (SLDB) Tops Q2 EPS by 7c

Thu, 06 Aug 2026 17:57:51 -0400

Solid Biosciences (NASDAQ: SLDB) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Solid Biosciences (SLDB) click here.

Form 8-K Solid Biosciences Inc. For: Aug 06

Thu, 06 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26885566.html

Form 8-K Solid Biosciences Inc. For: Aug 06

Thu, 06 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26885566.html

Form 424B5 Solid Biosciences Inc.

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885440.html

Form 424B5 Solid Biosciences Inc.

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885440.html

Form S-3ASR Solid Biosciences Inc.

Thu, 06 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26885310.html

Form S-3ASR Solid Biosciences Inc.

Thu, 06 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26885310.html

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:08:00 -0400

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 -

- Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -

- Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 -

- Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:08:00 -0400

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 -

- Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -

- Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 -

- Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:08:00 -0400

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 -

- Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -

- Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 -

- Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:08:00 -0400

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 -

- Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -

- Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 -

- Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical

Form 10-Q Solid Biosciences Inc. For: Jun 30

Thu, 06 Aug 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260806/26883600.html

Form 10-Q Solid Biosciences Inc. For: Jun 30

Thu, 06 Aug 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260806/26883600.html

Form SCHEDULE 13G Solid Biosciences Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:41:00 -0400
si-local-file:///var/storage/secattach/20260806/26881375.html

Form SCHEDULE 13G Solid Biosciences Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:41:00 -0400
si-local-file:///var/storage/secattach/20260806/26881375.html

Form SCHEDULE 13G Solid Biosciences Inc. Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:19:00 -0400
si-local-file:///var/storage/secattach/20260730/26841240.html

Form SCHEDULE 13G Solid Biosciences Inc. Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:19:00 -0400
si-local-file:///var/storage/secattach/20260730/26841240.html